PD-1 Protein (AA 25-167) (His tag)

Catalog No. ABIN2181605

Product Details

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Protein Type: Recombinant

Biological Activity: Active

Protein Characteristics: AA 25-167

Origin: Human

Source: HEK-293 Cells

Purification tag / Conjugate: This PD-1 protein is labelled with His tag.

Sequence: AA 25-167

Characteristics: This protein carries a polyhistidine tag at the C-terminus, and has a calculated MW of 16.77 kDa. The N-terminus Sequence Analysis is Leu 25. The reducing (R) protein migrates as 25-45 kDa in SDS-PAGE due to glycosylation.

Purity: >95 % as determined by SDS-PAGE.

Sterility: 0.22 μm filtered

Endotoxin Level: Less than 1.0 EU per μg by the LAL method.

Grade: HPLC verified

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: PBS, pH 7.4

Handling Advice: Please avoid repeated freeze-thaw cycles.

Storage: -20 °C

Storage Comment: No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).

References

Assi, Wong, Tipton, Mei, Wong, Razo, Chan, Howng, Sagert, Krimm, Diep, Jang, Nguyen, Lapuyade, Singson, Villanueva, Paidhungat, Liu, Rangan, Vasiljeva, West, Richardson, Irving, Daniel, Belvin et al.: "Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents. ..." in: Cancer immunology research, Vol. 9, Issue 12, pp. 1451-1464, (2022) (PubMed).

Curnock, Bossi, Kumaran, Bawden, Figueiredo, Tawar, Wiseman, Henderson, Hoong, Gonzalez, Ghadbane, Knight, ODwyer, Overton, Lucato, Smith, Reis, Page, Whaley, McCully, Hearty, Mahon, Weber: "Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors." in: JCI insight, Vol. 6, Issue 20, (2021) (PubMed).

Wang, Fei, Jing, Wu, Wu, Zhou, Ni, Chen, Xiong, Liu, Peng, Yu, Jiang, Liu: "Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit." in: mAbs, (2019) (PubMed).

Boohaker, Sambandam, Segura, Miller, Suto, Xu: "Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction." in: Cancer letters, Vol. 434, pp. 11-21, (2018) (PubMed).

Target Details

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Alternative Name: PD-1 (PDCD1 Products)

Synonyms: CD279 Protein, PD-1 Protein, PD1 Protein, SLEB2 Protein, hPD-1 Protein, hPD-l Protein, Ly101 Protein, Pdc1 Protein, programmed cell death 1 Protein, PDCD1 Protein, Pdcd1 Protein

Background: Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.

Molecular Weight: 16.8 kDa

NCBI Accession: NP_005009

Pathways: Cancer Immune Checkpoints